Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.83.

A number of equities research analysts have recently commented on the stock. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a research report on Thursday, February 20th. Robert W. Baird began coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price for the company. Lake Street Capital began coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set a "buy" rating and a $30.00 price target on the stock. Piper Sandler began coverage on shares of Beta Bionics in a research note on Monday, February 24th. They set an "overweight" rating and a $26.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th.

Institutional Trading of Beta Bionics

Several large investors have recently added to or reduced their stakes in BBNX. Rhumbline Advisers bought a new stake in Beta Bionics in the 1st quarter valued at $158,000. Evanson Asset Management LLC acquired a new position in shares of Beta Bionics during the first quarter valued at about $475,000. Bank of New York Mellon Corp bought a new stake in shares of Beta Bionics in the first quarter valued at about $316,000. Values First Advisors Inc. acquired a new stake in Beta Bionics during the first quarter worth about $457,000. Finally, Jennison Associates LLC acquired a new stake in Beta Bionics during the first quarter worth about $828,000.

Beta Bionics Stock Down 6.9%

NASDAQ:BBNX traded down $0.98 during midday trading on Friday, hitting $13.20. The stock had a trading volume of 175,753 shares, compared to its average volume of 479,099. The company's 50-day simple moving average is $12.56. Beta Bionics has a one year low of $8.89 and a one year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.